GILD vs AMGN
GILD and AMGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | AMGNAmgen Inc. |
|---|---|---|
| Market cap | $181.41B | $203.14B |
| P/E (TTM) | 21.6 | 23.3 |
| P/B | 15.34 | 17.38 |
| P/S | 6.2x | 5.5x |
| Dividend yield | 2.21% | 2.52% |
| Revenue | $30.46B(TTM) | $38.09B(TTM) |
| Revenue growth (YoY) | 2.4% | 10.0% |
| Net income | -$3.24B(TTM) | $8.74B(TTM) |
| Earnings growth (YoY) | 1672.9% | 88.5% |
| EPS, diluted | $-2.65(TTM) | $16.10(TTM) |
| EBIT margin | 34.0% | 24.7% |
| ROE | 71.9% | 66.0% |
| ROIC | 26.7% | 15.1% |
| 1y total return | +32.9% | +40.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: GILD vs AMGN
| Metric | GILD | AMGN |
|---|---|---|
| End value | $25.5K | $33.5K |
| Total return | +154.7% | +235.2% |
| CAGR | +9.5% | +12.4% |
| Volatility | 25.6% | 25.0% |
| Sharpe | 0.32 | 0.43 |
| Sortino | 0.48 | 0.63 |
| Max drawdown | -30.5% | -24.9% |
Based on 2600 common trading days, 2016-05-12 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)